{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T08:51:18Z","timestamp":1773651078428,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ck0106805"],"award-info":[{"award-number":["JP23ck0106805"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19kk0305010"],"award-info":[{"award-number":["JP19kk0305010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23tm0624002"],"award-info":[{"award-number":["JP23tm0624002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18km0605001"],"award-info":[{"award-number":["JP18km0605001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BRCA1 pathogenic variants are associated with a lower risk of developing prostate cancer than BRCA2, but aggressiveness remains unclear. Therefore, screening criteria are insufficiently established. Here, we reanalyzed the impact of BRCA1 pathogenic variants on aggressiveness using 11\u200a300 prostate cancer patients, adjusting for age and area. The proportion of aggressive prostate cancer was higher in BRCA1 carriers (86.7%) than in noncarriers (61.1%) (odds ratio = 4.87; 95% confidence interval = 1.05 to 22.60). The proportion of high prostate-specific antigen levels was higher in BRCA1 carriers (66.7%) than in noncarriers (27.9%) (P\u2009=\u20097.61\u2009\u00d7\u200910\u22123). BRCA1 carriers had a worse tendency than noncarriers for T classification (T3\u20134: BRCA1, 36.4%; noncarriers, 23.2%) and Gleason score (GS8\u201310: BRCA1, 53.3%; noncarriers, 31.0%). Moreover, we observed the first case of BRCA1-related aggressive prostate cancer showing long-term survival through early detection and multidisciplinary treatment. These results suggest that recommendations for early prostate cancer screening might need to be reconsidered for BRCA1 carriers.<\/jats:p>","DOI":"10.1093\/jncics\/pkaf118","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:05:22Z","timestamp":1765976722000},"source":"Crossref","is-referenced-by-count":0,"title":["Revisiting the impact of\n                    <i>BRCA1<\/i>\n                    pathogenic variants on the aggressiveness of prostate cancer"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-4955","authenticated-orcid":false,"given":"Hajime","family":"Sasagawa","sequence":"first","affiliation":[{"name":"Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences , Yokohama,","place":["Japan"]},{"name":"Department of Urology, Akita University Graduate School of Medicine , Akita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-1860","authenticated-orcid":false,"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine , Akita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-2686","authenticated-orcid":false,"given":"Koichi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-4594","authenticated-orcid":false,"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-3504","authenticated-orcid":false,"given":"Yukihide","family":"Momozawa","sequence":"additional","affiliation":[{"name":"Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences , Yokohama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2026031604012412200_pkaf118-B1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2022.12.021","article-title":"Genetic risk prediction for prostate cancer: implications for early detection and prevention","volume":"83","author":"Seibert","year":"2023","journal-title":"Eur Urol"},{"key":"2026031604012412200_pkaf118-B2","volume-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer","author":"Cornford","year":"2024"},{"key":"2026031604012412200_pkaf118-B3","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026031604012412200_pkaf118-B4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jnci\/djz124","article-title":"Germline pathogenic variants in 7636 Japanese patients with prostate cancer and 12 366 controls","volume":"112","author":"Momozawa","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2026031604012412200_pkaf118-B5","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.2147\/OTT.S264347","article-title":"Metastatic castration-resistant prostate cancer with neuroendocrine transformation and BRCA 1 germ-line mutation: a case report and literature review","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"2026031604012412200_pkaf118-B6","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.je.2016.12.003","article-title":"Cross-sectional analysis of BioBank Japan clinical data: a large cohort of 200,000 patients with 47 common diseases","volume":"27","author":"Hirata","year":"2017","journal-title":"J Epidemiol"},{"key":"2026031604012412200_pkaf118-B7","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.je.2016.12.005","article-title":"Overview of the BioBank Japan project: study design and profile","volume":"27","author":"Nagai","year":"2017","journal-title":"J Epidemiol"},{"key":"2026031604012412200_pkaf118-B8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026031604012412200_pkaf118-B9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2026031604012412200_pkaf118-B10","doi-asserted-by":"crossref","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","article-title":"ClinVar: public archive of interpretations of clinically relevant variants","volume":"44","author":"Landrum","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026031604012412200_pkaf118-B11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-025-56944-1","article-title":"Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases","volume":"16","author":"Mitchell","year":"2025","journal-title":"Nat Commun"},{"key":"2026031604012412200_pkaf118-B12","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026031604012412200_pkaf118-B13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"2026031604012412200_pkaf118-B14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat Genet"},{"key":"2026031604012412200_pkaf118-B15","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.7150\/jca.31454","article-title":"Elevated MRE11 expression associated with progression and poor outcome in prostate cancer","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"key":"2026031604012412200_pkaf118-B16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"key":"2026031604012412200_pkaf118-B17","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf118\/66049347\/pkaf118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/1\/pkaf118\/66049347\/pkaf118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/1\/pkaf118\/66049347\/pkaf118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T08:01:30Z","timestamp":1773648090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf118\/8385263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf118","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,19]]},"article-number":"pkaf118"}}